This article highlights key announcements from the 2026 AWS Life Sciences Symposium, focusing on how AI agents are accelerating drug discovery and research through integrated lab-in-the-loop workflows.

• Amazon Bio Discovery launched: unified AI-driven antibody discovery application with 40+ biological foundation models
• Memorial Sloan Kettering case study: designed 288,000 nanobody candidates, validated 46 binders in weeks
• Antibody Developability Benchmark Dataset released with Johns Hopkins for rigorous AI model evaluation
• Sanofi's SWEL platform: enterprise-scale lab-in-the-loop on AWS, 2-3x more projects, 10x faster deployment
• Roche's Galileo platform: production agentic AI serving 70,000 users across 90,000 connected lab instruments
• AI Structural Biology Network: federated model achieved 51% accuracy vs 34% baseline across nine pharma companies
• Noetik's human-data approach: foundation models trained on patient specimens achieved 56% objective response rate

The symposium demonstrated that agentic AI is now production infrastructure transforming drug discovery through context-aware orchestration, unified data foundations, and direct scientist access to powerful AI tools.